2-(1,4(1,4)-Dibenzenacyclohexaphane-12-yl)-5-(hydroxydiphenylmethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride, stereoisomer

Catalog No. :
ACYTYB762
CAS No. :
1410629-36-5
Molecular Formula :
C34H32ClN3O
Molecular Weight :
534.10

IUPAC Name:2-(1,4(1,4)-dibenzenacyclohexaphane-12-yl)-5-(hydroxydiphenylmethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride

2-(1,4(1,4)-Dibenzenacyclohexaphane-12-yl)-5-(hydroxydiphenylmethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride, stereoisomer structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(1,4(1,4)-Dibenzenacyclohexaphane-12-yl)-5-(hydroxydiphenylmethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride, stereoisomer
IUPAC Name2-(1,4(1,4)-dibenzenacyclohexaphane-12-yl)-5-(hydroxydiphenylmethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride
Molecular FormulaC34H32ClN3O
Molecular Weight534.10
SMILESOC(C1=CC=CC=C1)(C1=CC=CC=C1)C1CCC2=N[N+](C3=CC4=CC=C3CCC3=CC=C(C=C3)CC4)=CN21.[Cl-]
InChI KeyMFBXNUAFEABVCR-UHFFFAOYSA-M
Synonym5H-Pyrrolo[2,1-c]-1,2,4-triazolium, 6,7-dihydro-5-(hydroxydiphenylmethyl)-2-tricyclo[8.2.2.24,7]hexadeca-4,6,10,12,13,15-hexaen-5-yl-, chloride (1:1), stereoisomer
CAS No.1410629-36-5

Synthetic Route by SureRoute

1. ACYTYB762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYTYB762 route product structure diagram
    ACYTYB7621410629-36-5
Inquiry

2. ACYTYB762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACYTYB762 route product structure diagram
    ACYTYB7621410629-36-5
Inquiry

Comments (0)